drugset / Trial / NCT05960708
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following a single subcutaneous injection of YH35324 in subjects with various allergic diseases.
Timeline
- Start
- 2023-08-23
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omalizumab | Monoclonal antibody | — | Subcutaneous |
| Subject | YH35324 | Unknown | — | Subcutaneous |